RU K-EDGE EXAFS ANALYSIS OF A RUTHENIUM ANTICANCER DRUG-TRANSFERRIN ADDUCT

钌抗癌药物-转铁蛋白加合物的 RU K-EDGE EXAFS 分析

• 批准号: 8170241
• 负责人: KAREN MCFARLANE HOLMAN
• 金额: $ 0.03万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-05-01 至 2011-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8170241
• 关键词: Antineoplastic Agents; Biological Process; Chemical Structure; Computer Retrieval of Information on Scientific Projects Database; Drug Design; Funding; Grant; Institution; Research; Research Personnel; Resources; Ruthenium; Source; Transferrin; United States National Institutes of Health; adduct; base; in vitro activity; process optimization

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. We propose a systematic multi-edge XANES study to determine spectroscopic signatures for Ru-based anticancer metallodrugs that correlate with in vitro activity. This would make possible the prediction of biological function from chemical structure and thus aid the drug design and optimization process.

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 我们提出了一个系统的多边缘XANES研究，以确定光谱签名的钌基抗癌金属药物，在体外活性相关。这将使从化学结构预测生物功能成为可能，从而有助于药物设计和优化过程。